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Apolipoprotein E4 in the
temporal variant of
frontotemporal dementia
Although the apolipoprotein E4 (apoE4) allele
has consistently been associated with
Alzheimer’s disease and other types of de-
mentia in many studies,1 its association with
frontotemporal dementia (FTD) is controver-
sial. After our report in 1997 of increased
apoE4 allele frequencies in sporadic FTD and
its effect on the age at onset,2 other studies of
cases of FTD with pathological confirmation
or tau mutations did not confirm this
effect.3–5 However, recently it has been shown
that semantic dementia, the temporal variant
of FTD, may be associated with higher
frequencies of the apoE4 allele.6 Therefore, we
have genotyped apoE in our expanded FTD
patient population and have assessed whether
patients with predominance of temporal atro-
phy have higher frequencies of the apoE4
allele.
Patients were ascertained through a clini-
coepidemiological survey of patients with FTD
in The Netherlands.2 We identified 111 pa-
tients with the diagnosis of probable FTD,
established according to the Lund and Man-
chester criteria. Thirteen of the patients had
an autosomal dominant form (defined as at
least three affected family members in two
generations) of FTD, with tau mutations
identified in 10 (P301L, G272V, R406W, and
∆K280), and were excluded from further
analyses. Predominant temporal atrophy,
semiquantitatively assessed on CT and/or
MRI, was found in 31 (32%) patients, whereas
frontal atrophy with or without temporal
atrophy was present in 67 (68%) patients.
Nine of the 31 patients (29%) with temporal
atrophy fulfilled the criteria for semantic
dementia, and four patients (13%) showed
severe problems in language comprehension,
although the diagnosis of semantic dementia
could not be definitely established due to
incomplete or inconclusive neuropsychologi-
cal testing. The remaining 18 patients (58%)
showed mainly decreased spontaneous
speech and word finding difficulties. The
clinical diagnosis of FTD was pathologically
confirmed in all 17 patients who came to
postmortem (five of whom had predominant
temporal atrophy). Non-demented control
subjects (n=561) were taken from the Rotter-
dam study.7 All patients and controls were
genotyped for the apoE allele as described by
Slooter et al.1 Both genotype frequencies and
apoE4 allele frequencies were calculated for
each group and compared with non-
demented controls using a χ2 test.
Six per cent of the 98 patients with sporadic
FTD had the apoE4/E4 genotype, compared
with 2.3% of non-demented controls
(p=0.04). This genotype was present in 9.7%
of patients with the temporal variant of FTD
(p=0.01) compared with non-demented con-
trols), compared with only 4.5% in patients
with frontotemporal atrophy (p=0.5). Geno-
type frequencies of heterozygote E4 (E4/*)
and homozygote E4 (E4/E4) carriers are sum-
marised in table 1. The frequency of the apoE4
allele in all patients with sporadic FTD was
21.9%, compared with 15.3% in the non-
demented controls (p=0.02). In patients with
temporal atrophy the apoE4 allele frequency
was as high as 29.0% (p=0.004), whereas in
the patients with frontotemporal atrophy only
18.7% (p=0.3) of alleles was apoE4. No
association between ApoE4 and the age at
onset, nor the duration of symptoms, was
found in the overall group, nor in the
subgroups.
Our results show that the apoE4 allele
frequency is increased in patients with the
temporal variant of FTD compared with non-
demented controls. Although a biological hy-
pothesis justifying such an association is still
lacking, the effect of the apoE4 allele on the
predominance of temporal atrophy compared
with frontal atrophy has also been observed in
patients with Alzheimer’s disease.8 To verify the
association between the apoE4 allele and the
temporal variant of FTD, a large study with
pathological confirmation of the clinical diag-
nosis of FTD is required to exclude admixture
of patients with Alzheimer’s disease. However,
in all 17 patients who were necropsied in our
series, including five patients with temporal
lobe atrophy, the clinical diagnosis was neu-
ropathologically confirmed. This shows that
the clinical criteria according to the Lund and
Manchester groups, when combined with neu-
roimaging and psychometric evaluation, are
highly accurate. We conclude that the associ-
ation we previously found between the apoE4
allele and sporadic FTD may be due to a selec-
tive increase of this allele in patients with the
temporal variant of FTD.
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Transferrin C2 allele,
haemochromatosis gene
mutations, and risk for
Alzheimer’s disease
Alzheimer’s disease is a neurodegenerative
disease characterised pathologically by the
presence of neurofibrillary tangles, senile
plaques, and selective loss of neurons. Numer-
ous hypotheses have been suggested for the
aetiology and pathogenesis of Alzheimer’s
disease and one that has gained considerable
Table 1 Frequency of apoE genotypes and E4 alleles in different groups
Group Patients
Genotype† Alleles
E4/E4 E4/* No E4 %E4 P-value
Non-demented controls 561 2.3% 26.0% 71.7% 15.3 Reference
Sporadic FTD 98 6.1% 31.6% 62.3% 21.9 0.02
Temporal lobe atrophy 31 9.7% 38.7% 51.6% 29.0 0.004
Frontal lobe atrophy 67 4.5% 28.4% 67.1% 18.7 0.3
†E4/E4, E4 homozygotes; E4/*,E4 heterozygotes; No E4, all other genotypes.
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